anti-doping raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-02-10. Anything still debated is marked as such rather than presented as settled.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Skeletal muscle, is a type of striated muscle, composed of muscle cells, called muscle fibers, which are in turn composed of myofibrils. Myofibrils are composed of sarcomeres, the basic building blocks of striated muscle tissue. Upon stimulation by an action potential, skeletal muscles perform a coordinated contraction by shortening each sarcomere. The best proposed model for understanding contraction is the sliding filament model of muscle contraction. Within the sarcomere, actin and myosin fibers overlap in a contractile motion towards each other. Myosin filaments have club-shaped myosin heads that project toward the actin filaments, and provide attachment points on binding sites for the actin filaments. The myosin heads move in a coordinated style; they swivel toward the center of the sarcomere, detach, and then reattach to the nearest active site of the actin filament. This is called a ratchet-type drive system. This process consumes large amounts of adenosine triphosphate (ATP), the energy source of the cell. ATP binds to the cross-bridges between myosin heads and actin filaments. The release of energy powers the swiveling of the myosin head. When ATP is used, it becomes adenosine diphosphate (ADP), and since muscles store little ATP, they must continuously replace the discharged ADP with ATP. Muscle tissue also contains a stored supply of a fast-acting recharge chemical, creatine phosphate, which when necessary can assist with the rapid regeneration of ADP into ATP. Calcium ions are required for each cycle of the sarcomere.
== History == Turquoise was mined by pre-Columbian Native Americans in deposits in New Mexico (Los Cerrillos) and likely in California as well. Additionally, it was used by the Ancient Egyptians, although not very commonly. Several turquoise artefacts, such as beads and reclining calves, have also been found in Greece, dating to the Mycenaean era (1500BC). Turquoise mining later attracted brief European interest in the late 1800s. Prices peaked in 1890, then collapsed by 1912, ending large-scale operations. During Mohammad Khodabanda reign (1578–1587), accumulated turquoise dust from fifty years of mining in Safavid Iran was squandered lavishly, reflecting royal excess amid economic hardship, political discord, and rising factionalism among the qezelbash elite.
== Clinical use == European Association of Urology (EAU) guidelines recognise that PSMA can provide accurate staging, however there is a lack of outcome data to inform further management. The American Society of Clinical Oncology (ASCO) guidelines for imaging of advanced prostate cancer also recommend PSMA imaging (among other PET radiopharmaceuticals), while acknowledging that these are not FDA approved and therefore limited to a clinical trial or other controlled research setting. Although PSMA PET imaging has shown clear superiority over conventional CT and bone scans for detecting prostate cancer, comparative studies assessing different PSMA ligands, such as 68Ga-PSMA-11 and 18F-DCFPyL, remain limited. A 2024 overview of reviews published in Seminars of Nuclear Medicine concluded that while evidence gaps remain for some outcomes and most systematic reviews are at high or unclear risk of bias, the evidence base is broadly supportive of 18F PSMA PET/CT in patients with high-risk prostate cancer or biochemical recurrence
To achieve Type I, humanity must be able to communicate with the rest of the world and to focus on several areas: building infrastructure to facilitate communication and cooperation, education, research and development, and innovation, as well as building strong ties between diasporas and their countries of origin, and between migrants and non-migrants. If development fails, it is likely that the world will not be able to achieve Type II. If these areas do not develop, Kaku predicts that humanity will sink into the "abyss": an advanced civilization must grow faster than the frequency of occurrence of extinction-level cosmic catastrophes, such as comet or asteroid impacts. A Type I civilization should also be able to master space travel to deflect threatening objects. It would also have to anticipate the onset of ice ages and modify the climate long before they occur to avoid them. In addition, in his books Hyperspace and Parallel Worlds, Michio Kaku has discussed a Type IV civilization that could harness "extragalactic" energy sources such as dark energy.
Sources: en.wikipedia.org
In their discovery of elements 99 and 100, the American teams had competed with a group at the Nobel Institute for Physics, Stockholm, Sweden. In late 1953 to early 1954, the Swedish group succeeded in synthesizing light isotopes of element 100, in particular 250Fm, by bombarding uranium with oxygen nuclei. These results were also published in 1954. Nevertheless, the priority of the Berkeley team was generally recognized, as its publications preceded the Swedish article, and they were based on the previously undisclosed results of the 1952 thermonuclear explosion; thus the Berkeley team was given the privilege to name the new elements. As the effort which had led to the design of Ivy Mike was codenamed Project PANDA, element 99 had been jokingly nicknamed "Pandemonium" but the official names suggested by the Berkeley group derived from two prominent scientists, Einstein and Fermi: "We suggest for the name for the element with the atomic number 99, einsteinium (symbol E) after Albert Einstein and for the name for the element with atomic number 100, fermium (symbol Fm), after Enrico Fermi." Both Einstein and Fermi died between the time the names were originally proposed and when they were announced. The discovery of these new elements was announced by Albert Ghiorso at the first Geneva Atomic Conference held on 8–20 August 1955. The symbol for einsteinium was first given as "E" and later changed to "Es" by IUPAC.
== "The Triumph of Vulgar Rationalism" (2012) == Amid intense public debate surrounding the Cologne Regional Court's 2012 ruling on circumcision, Kermani published an article in the daily newspaper Süddeutsche Zeitung titled "The Triumph of Vulgar Rationalism". In this article, Kermani accused the Cologne Regional Court of "casually and in the blink of an eye declaring four thousand years of religious history obsolete". The Enlightenment, Kermani argues, does not merely signify the rule of reason, but also an acknowledgment of reason's limitations. "Then again, vulgar rationalism—as expressed in the Cologne Regional Court's ruling—elevates one's own, that is, contemporary, understanding to an absolute, unconditional value." Joachim Gauck has since adopted the term vulgar rationalism in his statements on the circumcision debate.
==== Clinical Laboratory Improvement Amendments (CLIA) ==== CMS ensures the integrity of laboratories performing testing via inspections and consistent oversight, bolstered with proficiency testing by accredited organizations. CLIA authorizes regulation of laboratories that conduct testing, not the individuals who order the tests or receive test results. All laboratories performing DTC testing must obtain CLIA certification and maintain compliance with national standards.
== Medical uses == Beta blockers are utilized in the treatment of various conditions related to the heart and vascular system, as well as several other medical conditions. Common heart-related conditions for which beta blockers are well-established include angina pectoris, acute coronary syndromes, hypertension, and arrhythmias such as atrial fibrillation and heart failure. They are also used in the management of other heart diseases, such as hypertrophic obstructive cardiomyopathy, mitral valve stenosis or prolapse, and dissecting aneurysm. Additionally, beta blockers find applications in vascular surgery, the treatment of anxiety states, cases of thyrotoxicosis, glaucoma, migraines, and esophageal varices.
Complicated intra-abdominal infections; Acute pyelonephritis; Complicated urinary tract infections. Hospital-acquired bacterial pneumonia and Ventilator-associated bacterial pneumonia (HABP/VABP) In addition, ceftolozane/tazobactam has demonstrated stability for administration by continuous infusion, including delivery via elastomeric pumps. This pharmacotechnical property supports its use in outpatient parenteral antimicrobial therapy (OPAT) programs, particularly for time-dependent β-lactam optimization and carbapenem-sparing strategies. In real-world OPAT cohorts, ceftolozane/tazobactam accounted for approximately 7.5% of antibiotics administered by continuous infusion.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.